Skip to content

Author

K. Fujihara

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Performance of the international 2023 myelin oligodendrocyte glycoprotein antibody-associated disease panel criteria in a Japanese cohort: combined assessment of myelin oligodendrocyte glycoprotein immunoglobulin G in serum and CSF

In the 2023 International Panel’s diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), one of six core clinical demyelinating events (core events) is required: optic neuritis (ON), myelitis, acute disseminated encephalomyelitis (ADEM), cerebral monofocal or polyfocal defici...

Y. Matsumoto, Naoki Yamamoto, K. Kaneko et al. · 0 citations
Review Sep 2026

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review.

Importance Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...

Eoin P. Flanagan, Brenda L. Banwell, Laura Cacciaguerra et al. · 0 citations
Open access Aug 2026

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan

The safety profile of inebilizumab was consistent with prior evidence and no new safety concerns were identified, and inebilizumab reduced relapse rates and decreased concomitant use of oral glucocorticoids and immunosuppressants in patients with NMOSD.

K. Fujihara, Shinya Hirota, Muneyoshi Kudo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.